| 1. |
Suzuki M, Asahina H, Konishi J, et al. Recurrent gefitinibinduced interstitial lung disease. Intern Med, 2008, 47 : 533-536.
|
| 2. |
Kuo LC, Lin PC, Wang KF, et al. Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol,2011, 28 : 79 -82.
|
| 3. |
Kitajima H, Takahashi H, Harada K, et al. Gefitinib-induced interstitial lung disease showing improvement after cessation:disassociation of serum markers. Respirology, 2006 , 11: 217 -220.
|
| 4. |
Brehmer D, Greff Z, Godl K, et al. Cellular targets of gefitinib.Cancer Res, 2005 , 65: 379 -382.
|
| 5. |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009 ,361: 947-957.
|
| 6. |
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362: 2380-2388.
|
| 7. |
Suzuki H, Aoshiba K, Yokohori N, et al. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res, 2003, 63: 5054-5059.
|
| 8. |
Harada C, Kawaguchi T, Ogata-Suetsugu S, et al. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Am J Respir Crit Care Med, 2011, 183: 743 -.
|
| 9. |
Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol,.
|
| 10. |
Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med, 2008 , 177 : 1348 -1357 .
|
| 11. |
Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib ( ZD1839 ; Iressa ) tablets. Clin Cancer Res, 2004, 10: 1212 -1218.
|
| 12. |
Seto T, Seki N, Uematsu K, et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology,2006, 11 : 113-116.
|
| 13. |
高宝安, 丁琳, 詹庆元, 等. 无创正压通气治疗急性低氧性呼吸衰竭前瞻性队列研究. 中国危重病急救医学, 2009, 21: 579 -582.
|
| 14. |
Chang SC, Chang CY, Chen CY, et al. Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol, 2010, 5: 1105-1106.
|
| 15. |
Fukui T, Otani S, Hataishi R, et al. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. CancerChemother Pharmacol, 2010 , 65: 803-806.
|
| 16. |
Dallas JL, Jantz MA, Lightsey JL, et al. Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease. J Thorac Oncol, 2011, 6: 1142-1143.
|
| 17. |
.
|
| 18. |
, 24 : 2549 -2556.
|
